1. Home
  2. BCDA vs INTJ Comparison

BCDA vs INTJ Comparison

Compare BCDA & INTJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • INTJ
  • Stock Information
  • Founded
  • BCDA N/A
  • INTJ 2016
  • Country
  • BCDA United States
  • INTJ Hong Kong
  • Employees
  • BCDA N/A
  • INTJ N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • INTJ
  • Sector
  • BCDA Health Care
  • INTJ
  • Exchange
  • BCDA Nasdaq
  • INTJ NYSE
  • Market Cap
  • BCDA 11.5M
  • INTJ 12.7M
  • IPO Year
  • BCDA N/A
  • INTJ 2024
  • Fundamental
  • Price
  • BCDA $2.31
  • INTJ $0.95
  • Analyst Decision
  • BCDA Strong Buy
  • INTJ
  • Analyst Count
  • BCDA 1
  • INTJ 0
  • Target Price
  • BCDA $25.00
  • INTJ N/A
  • AVG Volume (30 Days)
  • BCDA 69.0K
  • INTJ 80.0K
  • Earning Date
  • BCDA 03-26-2025
  • INTJ 11-01-2024
  • Dividend Yield
  • BCDA N/A
  • INTJ N/A
  • EPS Growth
  • BCDA N/A
  • INTJ 30.19
  • EPS
  • BCDA N/A
  • INTJ 0.07
  • Revenue
  • BCDA $71,000.00
  • INTJ $2,341,977.00
  • Revenue This Year
  • BCDA N/A
  • INTJ N/A
  • Revenue Next Year
  • BCDA N/A
  • INTJ N/A
  • P/E Ratio
  • BCDA N/A
  • INTJ $13.66
  • Revenue Growth
  • BCDA N/A
  • INTJ 25.78
  • 52 Week Low
  • BCDA $1.63
  • INTJ $0.72
  • 52 Week High
  • BCDA $8.85
  • INTJ $7.87
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 45.73
  • INTJ N/A
  • Support Level
  • BCDA $2.27
  • INTJ N/A
  • Resistance Level
  • BCDA $2.95
  • INTJ N/A
  • Average True Range (ATR)
  • BCDA 0.26
  • INTJ 0.00
  • MACD
  • BCDA -0.02
  • INTJ 0.00
  • Stochastic Oscillator
  • BCDA 22.89
  • INTJ 0.00

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About INTJ INTELLIGENT GROUP LTD

Intelligent Group Ltd is a professional services provider in Hong Kong that principally engages in the provision of Financial PR services. The company provides a substantial number of holistic and comprehensive Financial PR services to its clients through IJL, its key operating entity in Hong Kong. It advises its clients on their communications and reputation management efforts. Its Financial PR services include creating multi-stakeholder communications programs, arranging press conferences and interviews, participating in the preparation of news releases and shareholders' meetings, monitoring news publications, identifying shareholders, targeting potential investors, organizing corporate events, and implementing crisis management policies and procedures.

Share on Social Networks: